Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Antiviral Res. 2019 May 31;168:134–145. doi: 10.1016/j.antiviral.2019.05.015

Figure 4. ONC201 reduces HIV-1 infection levels in NSG mouse brains engrafted with infected human macrophages.

Figure 4.

HIV-1-infected human macrophages were intracranially injected into the basal ganglia of NOD/scid-IL-2Rgcnull (NSG) mice. Mice were administrated daily with ONC201 (50 mg/kg) or solvent control DMSO through intraperitoneal injections. A) Timeline of experimental procedures and sample collection in the HIV-1-infected NSG mouse model. B-J) Immunostaining of p24 and CD68 in the injection sites of mouse brains: co-immunostaining of p24 and DAPI (B-G); co-immunostaining of CD68 and DAPI (H-I); quantification of the p24/CD68 ratio per area (J). K-M) Brain tissues that contained the injection sites were homogenized for detection of HIV-1 p24 and human CD68 in Western blots. Data were evaluated statistically by an unpaired Student’s t-test, n = 6 per treatment group.